OSLO, Norway, March 10, 2020 /PRNewswire/ -- Financial calendar for Nordic Nanovector ASA
FINANCIAL YEAR 2019
27.03.2020 - Annual Report
FINANCIAL YEAR 2020
27.08.2020 - Half-yearly Report
30.04.2020 - Annual General Meeting
26.05.2020 - Quarterly Report - Q1
19.11.2020 - Quarterly Report - Q3
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
For further information, please contact:
VP Investor Relations and Corporate Communications
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Further information can be found at www.nordicnanovector.com.
This information is published pursuant to the requirements set out in the Continuing obligations.
This information was brought to you by Cision http://news.cision.com
SOURCE Nordic Nanovector